UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Frontline Maintenance Treatment for Ovarian Cancer

Elyashiv, O; Wong, YNS; Ledermann, JA; (2021) Frontline Maintenance Treatment for Ovarian Cancer. Current Oncology Reports , 23 (8) , Article 97. 10.1007/s11912-021-01088-w. Green open access

[thumbnail of Ledermann_Frontline Maintenance Treatment for Ovarian Cancer_VoR.pdf]
Preview
Text
Ledermann_Frontline Maintenance Treatment for Ovarian Cancer_VoR.pdf - Published Version

Download (386kB) | Preview

Abstract

PURPOSE OF REVIEW: Advanced epithelial ovarian cancer remains the most lethal gynaecological cancer. Most patients with advanced disease will relapse within 3 years after primary treatment with surgery and chemotherapy. Recurrences become increasing difficult to treat due to the emergence of drug resistance and 5-year survival has changed little over the last decade. Maintenance treatment, here defined as treatment given beyond primary chemotherapy, can both consolidate the response and prolong the control of disease which is an approach to improve survival. RECENT FINDINGS: Here we review maintenance strategies such as targeting angiogenesis, interference of DNA repair through inhibition of PARP, combinations of targeting agents, and immunotherapy and hormonal therapy. Much has been learnt from the success and challenges of these treatments that have in the last few years which led to significant reduction in disease recurrence, changed the guidelines for treatment, and established a new paradigm for the treatment of ovarian cancer.

Type: Article
Title: Frontline Maintenance Treatment for Ovarian Cancer
Location: United States
Open access status: An open access version is available from UCL Discovery
DOI: 10.1007/s11912-021-01088-w
Publisher version: http://dx.doi.org/10.1007/s11912-021-01088-w
Language: English
Additional information: Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Keywords: Antiangiogenic agents, Checkpoint inhibitors, Combined targeted therapies, Epithelial ovarian cancer, Fallopian tube cancer, Frontline maintenance treatment, Hormonal maintenance treatment, PARP inhibitors, Primary peritoneal cancer, Targeted therapies
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > CRUK Cancer Trials Centre
URI: https://discovery.ucl.ac.uk/id/eprint/10129981
Downloads since deposit
42Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item